Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMA NASDAQ:INAB NASDAQ:IZTC NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.61-5.2%$5.71$3.94▼$18.00$59.11M0.73259,683 shs17,642 shsINABIN8bio$1.60$1.60$1.17▼$5.61$15.76M0.0871,297 shs9,584 shsIZTCInvizyne Technologies$10.54+6.6%$8.99$8.50▼$23.00$65.90MN/A37,647 shs1,772 shsPYRGFPyroGenesis Canada$0.31+5.6%$0.36$0.12▼$0.53$64.22M0.2654,231 shs36,717 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio-2.80%-1.83%+24.42%-14.47%-54.82%INABIN8bio+1.27%+8.84%+11.89%-19.60%-67.28%IZTCInvizyne Technologies+6.59%+1.84%+4.88%-2.86%-2.00%PYRGFPyroGenesis Canada-2.65%+5.95%-17.18%+49.39%-8.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.61-5.2%$5.71$3.94▼$18.00$59.11M0.73259,683 shs17,642 shsINABIN8bio$1.60$1.60$1.17▼$5.61$15.76M0.0871,297 shs9,584 shsIZTCInvizyne Technologies$10.54+6.6%$8.99$8.50▼$23.00$65.90MN/A37,647 shs1,772 shsPYRGFPyroGenesis Canada$0.31+5.6%$0.36$0.12▼$0.53$64.22M0.2654,231 shs36,717 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio-2.80%-1.83%+24.42%-14.47%-54.82%INABIN8bio+1.27%+8.84%+11.89%-19.60%-67.28%IZTCInvizyne Technologies+6.59%+1.84%+4.88%-2.86%-2.00%PYRGFPyroGenesis Canada-2.65%+5.95%-17.18%+49.39%-8.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMAImageneBio 2.00Hold$26.50372.79% UpsideINABIN8bio 2.00Hold$4.00150.00% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INAB, IZTC, PYRGF, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026INABIN8bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026INABIN8bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMAImageneBio$800K74.62N/AN/A$11.91 per share0.47INABIN8bioN/AN/AN/AN/A$2.82 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada$9.14M7.03N/AN/A($0.01) per share-31.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMAImageneBio-$45.35M-$8.07N/AN/AN/AN/A-35.77%-31.78%N/AINABIN8bio-$19.44M-$4.45N/AN/AN/AN/A-111.30%-88.07%N/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada-$21.12M-$0.05N/AN/AN/A-115.14%N/A-60.81%N/ALatest INAB, IZTC, PYRGF, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A5/7/2026Q1 2026INABIN8bio-$0.59-$0.26+$0.33-$0.26N/AN/A3/12/2026Q4 2025INABIN8bio-$0.18-$0.26-$0.08-$0.26N/AN/A3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMAImageneBioN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMAImageneBioN/A12.4912.49INABIN8bioN/A8.828.82IZTCInvizyne TechnologiesN/AN/AN/APYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMAImageneBio75.00%INABIN8bio92.05%IZTCInvizyne TechnologiesN/APYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipIMAImageneBio5.94%INABIN8bio14.50%IZTCInvizyne TechnologiesN/APYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMAImageneBio7010.65 million10.02 millionNot OptionableINABIN8bio209.85 million8.42 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/APYRGFPyroGenesis Canada90206.84 million96.34 millionNo DataINAB, IZTC, PYRGF, and IMA HeadlinesRecent News About These CompaniesPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% ...May 7 at 12:53 AM | caledonianrecord.comCPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022May 7 at 7:00 PM | globenewswire.comPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Shares Up 5.3% - Here's WhyApril 21, 2026 | marketbeat.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comPyroGenesis Confirms Successful Primary Test Campaign with Leading Battery RecyclerMarch 6, 2026 | theglobeandmail.comPyroGenesis Completes Plasma Torch System Build for Constellium, Commences Delivery and Installation PhaseMarch 6, 2026 | globenewswire.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major Requirement for Proposed Joint VentureFebruary 19, 2026 | markets.businessinsider.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major ...February 19, 2026 | caledonianrecord.comCPyroGenesis Confirms Additional Independent Verification of Its Fumed Silica Meeting Commercial Grade “150”February 3, 2026 | globenewswire.comPyroGenesis Signs Agreement with U.S. Defense Contractor to Jointly Pursue Chemical Weapon Destruction Contracts in SyriaJanuary 6, 2026 | globenewswire.comPyroGenesis Provides 90-Day Cancellation Notice to EarthGridDecember 23, 2025 | globenewswire.comPyroGenesis Delivers 3.5 Tonnes of Titanium Powder Under New Powder Supply Agreement with U.S. Minerals and Metal Technology CompanyDecember 15, 2025 | globenewswire.comPyroGenesis Signs Plasma-Based Contract With Leading Battery RecyclerDecember 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Rust to Riches: The Great Resource Realignment By Jeffrey Neal Johnson | April 9, 2026INAB, IZTC, PYRGF, and IMA Company DescriptionsImageneBio NASDAQ:IMA$5.60 -0.31 (-5.16%) As of 11:24 AM Eastern This is a fair market value price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.IN8bio NASDAQ:INAB$1.60 0.00 (0.00%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. Invizyne Technologies NASDAQ:IZTC$10.54 +0.65 (+6.59%) As of 05/6/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.PyroGenesis Canada NASDAQ:PYRGF$0.31 +0.02 (+5.61%) As of 10:47 AM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
